Form 4: Kymera Therapeutics Director Jeffrey W. Albers Executes Stock Option and Sells Shares

Director Jeffrey W. Albers of Kymera Therapeutics, Inc. exercised a stock option and sold 5,000 shares of common stock on August 26, 2024, according to a Form 4 filing with the SEC.

Summary

• On August 26, 2024, Jeffrey W. Albers, a director of Kymera Therapeutics, Inc., executed a stock option to acquire 5,000 shares of common stock at a price of $10.34 per share.
• Simultaneously, Albers sold 5,000 shares of Kymera Therapeutics common stock at a weighted average price of $49.1017, with individual sales ranging from $49.00 to $49.32.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 22, 2023.
• Following these transactions, Albers directly owns 0 shares of Kymera Therapeutics common stock and 11,349 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This filing reflects routine transactions by a company insider and is typical for executives who receive stock options as part of their compensation. The use of a 10b5-1 trading plan suggests a pre-planned and orderly approach to selling shares.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the sale mitigates potential concerns about insider trading.

Key Dates